Biotechnological Approaches on Two High CBD and CBG Cannabis sativa L. (Cannabaceae) Varieties: In Vitro Regeneration and Phytochemical Consistency Evaluation of Micropropagated Plants Using Quantitative 1H-NMR DOI Creative Commons
Kostas Ioannidis, Evangelos Dadiotis,

Vangelis Mitsis

et al.

Molecules, Journal Year: 2020, Volume and Issue: 25(24), P. 5928 - 5928

Published: Dec. 15, 2020

High cannabidiol (CBD) and cannabigerol (CBG) varieties of Cannabis sativa L., a species with medicinal properties, were regenerated in vitro. Explants nodal segments including healthy axillary bud, after sterilization, placed Murashige-Skoog (MS) culture medium. The shoots formed 30 days subcultured full- or half-strength MS medium supplemented several concentrations 6-benzyl-amino-purine (BA) thidiazuron (TDZ). highest average number length was achieved when both full media 4.0 μM BA. presence TDZ showed also comparable results. BA at 4.0, 8.0 2.0, respectively, displayed the maximum shooting frequency. new transferred on same either self-rooted being enhanced different indole-3-butyric acid (IBA) α-naphthalene acetic (NAA). Presence 2.0 IBA NAA resulted to optimum rooting rates. roots per shoot observed NAA. Approximately 92% plantlets successfully established acclimatized field. consistency chemical profile vitro propagated clones assessed using quantitative 1H-NMR high throughput screening. In each variety, analysis micropropagated plant comparison mother no statistically significant differences (p ≤ 0.05) CBD+ cannabidiolic (CBDA) CBG+ cannabigerolic (CBGA) content thus indicating stability their profile.

Language: Английский

A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential DOI
C Michael White

The Journal of Clinical Pharmacology, Journal Year: 2019, Volume and Issue: 59(7), P. 923 - 934

Published: Feb. 7, 2019

Abstract Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from US Food and Drug Administration (FDA)‐approved called Epidiolex to created medical marijuana dispensaries sold in smoke shops, convenience stores, over Internet. The legal status of non–FDA‐approved differs depending on source state, while consistency quality vary markedly. Without independent laboratory verification, it impossible know whether labeled dosage correct, that delta‐9‐tetrahydrocannabinol content <0.3%, free adulteration contamination. On Internet, has been ailments which not studied, those diseases with evaluable human data, generally weak or very evidence. control refractory seizures clear exception, strong evidence CBD's benefit. Acute dosing before anxiety‐provoking events like public speaking chronic use schizophrenia promising but proven. risk free, adverse (primarily somnolence gastrointestinal nature) drug interactions. shown increase liver function tests needs further study assess its impact suicidal ideation.

Language: Английский

Citations

213
Efficacy of cannabidiol alone or in combination with Δ‐9‐tetrahydrocannabinol for the management of substance use disorders: An umbrella review of the evidence DOI Creative Commons
Bertrand Redonnet,

Filiz Eren,

Guillaume Avenin

et al.

Addiction, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 13, 2025

Abstract Background and Aims Substance use disorders (SUD) lead to a high burden of disease, yet treatment options are limited. Cannabidiol (CBD) is being investigated as potential therapeutic target due its pharmacological properties mode action in the endocannabinoid system. Recent systematic reviews (SR) on CBD SUDs have shown inconsistent results. The objective this umbrella review was determine whether alone or combination with Δ‐9‐tetrahydrocannabinol (THC) effective for managing treating SUDs. Methods Following registered protocol, we searched PubMed, Web Science Epistemonikos databases SRs, without meta‐analysis, randomized controlled trials focusing interventions dispensing CBD, THC, treat SUDs, published from 1 January 2000 15 October 2024. Screening, data extraction quality assessment AMSTAR 2 tool were performed by two researchers parallel duplicated. Results 22 SRs included, 5 which meta‐analysis. We found mixed evidence regarding efficacy manage Findings interpreted light SRs. Nabiximols, contains demonstrated positive effects cannabis withdrawal craving symptoms. Evidence supporting limited inconclusive abstinence, reduction cessation cannabis, tobacco, alcohol, opiates other psychoactive substances. Conclusion monotherapy does not appear be efficacious substance disorders. primarily exhibits when combined (THC). Existing regard outcomes related

Language: Английский

Citations

2
Cannabidiol (CBD) use in psychiatric disorders: A systematic review DOI

Stefania Bonaccorso,

A Ricciardi,

Caroline Zangani

et al.

NeuroToxicology, Journal Year: 2019, Volume and Issue: 74, P. 282 - 298

Published: Aug. 11, 2019

Language: Английский

Citations

142
Cannabidiol attenuates the rewarding effects of cocaine in rats by CB2, 5-HT1A and TRPV1 receptor mechanisms DOI
Ewa Galaj,

Guo‐Hua Bi,

Hongju Yang

et al.

Neuropharmacology, Journal Year: 2019, Volume and Issue: 167, P. 107740 - 107740

Published: Aug. 19, 2019

Language: Английский

Citations

106
Measuring Disturbance of the Endocannabinoid System in Psychosis DOI Open Access
Amedeo Minichino, Morwenna Senior, Natascia Brondino

et al.

JAMA Psychiatry, Journal Year: 2019, Volume and Issue: 76(9), P. 914 - 914

Published: June 5, 2019

The endocannabinoid system (ECS) is a lipid-based endogenous signaling system. Its relevance to psychosis through the association between cannabis use and onset course of illness antipsychotic properties cannabidiol, potential ECS enhancer.To conduct systematic review meta-analysis blood cerebrospinal fluid (CSF) measures in psychotic disorders.Web Science PubMed were searched from inception June 13, 2018. articles identified reviewed, as citations previous publications reference lists retrieved articles.Original included that reported or CSF activity patients with illnesses healthy controls.PRISMA guidelines, independent extraction by multiple observers, random-effects used. Heterogeneity was assessed I2 index. Sensitivity analyses tested robustness results.The clinical modifications disorders investigated (1) quantitative synthesis differences markers controls, (2) qualitative these symptom severity, stage illness, response treatment.A total 18 studies included. Three individual meta-analyses performed identify people schizophrenia controls. Five studies, including 226 385 significantly higher concentrations anandamide than controls (standardized mean difference [SMD], 0.97; 95% CI, 0.67-1.26; P < .001; = 54.8%). In 9 344 411 levels found patients, compared (SMD, 0.55; 0.05-1.04; .03; 89.6%). 3 involving 88 179 expression type 1 cannabinoid receptors on peripheral immune cells 0.57; 0.31-0.84; 0%). Higher tone at an early individuals who naïve free, it had inverse severity normalized after successful treatment. Moderate high level heterogeneity methods studies.Testing clinically relevant appears possible, provide useful biomarkers for disorder; however, not all accounted important variables, such use.PROSPERO identifier: CRD42018099863.

Language: Английский

Citations

96
Inclusion complexes of cannabidiol with β-cyclodextrin and its derivative: Physicochemical properties, water solubility, and antioxidant activity DOI
Hang Li, Senlin Chang, Tanran Chang

et al.

Journal of Molecular Liquids, Journal Year: 2021, Volume and Issue: 334, P. 116070 - 116070

Published: April 8, 2021

Language: Английский

Citations

83
Clinical uses of cannabis and cannabinoids in the United States DOI
Erik A. Levinsohn, Kevin P. Hill

Journal of the Neurological Sciences, Journal Year: 2020, Volume and Issue: 411, P. 116717 - 116717

Published: Jan. 30, 2020

Language: Английский

Citations

79
The therapeutic role of Cannabidiol in mental health: a systematic review DOI Creative Commons
Rabia Khan, Sadiq Naveed,

Nadeem Mian

et al.

Journal of Cannabis Research, Journal Year: 2020, Volume and Issue: 2(1)

Published: Jan. 2, 2020

Abstract Background The therapeutic application of cannabidiol (CBD) is gaining interest due to expanding evidence for its use. Objective To summarize the clinical outcomes, study designs and limitations use CBD nabiximols (whole plant extract from Cannabis sativa L. that has been purified into 1:1 ratio delta-9-tetrahydrocannabinol) in treatment psychiatric disorders. Materials method A systematic review was conducted including case reports, series, open-label trials, non-randomized randomized controlled trials (RCTs). search resulted 23 relevant studies on a wide range quality judged by using Oxford Centre Evidence-Based Medicine 2011 Levels Evidence ranges Level 1 5 based design. These levels help grading recommendations, Grade (strong), B (moderate), C (weak), D (weakest). Results CBD-containing compounds such as were helpful alleviating psychotic symptoms cognitive impairment patients with variety conditions, several provided effectiveness cannabis withdrawal moderate severe disorder recommendation. There recommendation supporting schizophrenia, social anxiety autism spectrum (ASD), attention deficit hyperactivity (ADHD). exists insomnia, anxiety, bipolar disorder, posttraumatic stress Tourette syndrome. recommendations should be considered context limited number available studies. Conclusion cannabis-related disorders, comorbidities ASD, ADHD However, there weaker disorders needs explored future studies, especially large-scale well-designed RCTs.

Language: Английский

Citations

79
Emerging evidence for the antidepressant effect of cannabidiol and the underlying molecular mechanisms DOI
Gabriela Pandini Silote, Ariandra Guerini Sartim, Amanda J. Sales

et al.

Journal of Chemical Neuroanatomy, Journal Year: 2019, Volume and Issue: 98, P. 104 - 116

Published: April 27, 2019

Language: Английский

Citations

76
Cannabidiol Treatment Might Promote Resilience to Cocaine and Methamphetamine Use Disorders: A Review of Possible Mechanisms DOI Creative Commons
Claudia Calpe-López, Maria Pilar García-Pardo, M.A. Aguilar

et al.

Molecules, Journal Year: 2019, Volume and Issue: 24(14), P. 2583 - 2583

Published: July 16, 2019

Currently, there are no approved pharmacotherapies for addiction to cocaine and other psychostimulant drugs. Several studies have proposed that cannabidiol (CBD) could be a promising treatment substance use disorders. In the present work, authors describe scarce preclinical human research about actions of CBD on effects stimulant drugs, mainly methamphetamine (METH). Additionally, possible mechanisms underlying therapeutic potential disorders reviewed. has reversed toxicity seizures induced by cocaine, behavioural sensitization amphetamines, motivation self-administer METH, context- stress-induced reinstatement priming-induced METH seeking behaviours. also potentiated extinction cocaine- amphetamine-induced conditioned place preference (CPP), impaired reconsolidation CPP prevented CPP. Observational suggest may reduce problems related with crack-cocaine addiction, such as withdrawal symptoms, craving, impulsivity paranoia (Fischer et al., 2015). The involved in protective drugs include prevention drug-induced neuroadaptations (neurotransmitter intracellular signalling pathways changes), erasure aberrant drug-memories, reversion cognitive deficits alleviation mental comorbid abuse. Further, future clinical trials necessary fully evaluate an intervention addictive

Language: Английский

Citations

70